Soleno Therapeutics (NASDAQ: SLNO) grants RSUs and stock options to SVP

Q: What insider transaction did Soleno Therapeutics (SLNO) disclose for Kristen Yen?

The company disclosed that officer Kristen Yen received 10,400 restricted stock units of Common Stock and an employee stock option for 11,900 shares, both granted on January 21, 2026 .

Q: How many Soleno Therapeutics (SLNO) shares does Kristen Yen beneficially own after this Form 4?

Following the reported transactions, Kristen Yen beneficially owned 37,639 shares of Soleno Therapeutics Common Stock directly, in addition to 11,900 stock options.

Q: What are the vesting terms of Kristen Yen’s RSUs at Soleno Therapeutics (SLNO)?

The 10,400 RSUs granted to Kristen Yen are scheduled to vest 100% on December 15, 2027 , provided she continues as a service provider under the company’s 2014 Equity Incentive Plan through that date.

Q: What are the key details of Kristen Yen’s stock option grant from Soleno Therapeutics (SLNO)?

The employee stock option covers 11,900 shares of Common Stock at an exercise price of $43.65 per share. Vesting begins on February 1, 2026, with 1/48th of the shares vesting each month, conditioned on continued service.

Q: Is Kristen Yen a director or officer of Soleno Therapeutics (SLNO)?

According to the filing, Kristen Yen is an officer of Soleno Therapeutics, serving as SVP Global Clinical Operations and Patient Advocacy . She is not listed as a director or 10% owner.

Q: Does the Soleno Therapeutics (SLNO) Form 4 involve any stock sales by Kristen Yen?

No stock sales are reported. The Form 4 reflects acquisitions of equity awards: 10,400 RSUs of Common Stock and an option for 11,900 shares, both granted for a price of $0 per unit.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Soleno Therapeutics reported new equity awards for officer Kristen Yen, its SVP Global Clinical Operations and Patient Advocacy. On January 21, 2026, Yen received 10,400 shares of Common Stock for no cash cost, structured as restricted stock units. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s 2014 Equity Incentive Plan.

Yen also received an employee stock option covering 11,900 shares of Common Stock at an exercise price of $43.65 per share. This option begins vesting on February 1, 2026, with 1/48th of the shares vesting monthly thereafter, contingent on continued service. After these transactions, she beneficially owned 37,639 shares of Common Stock directly, along with 11,900 stock options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Yen Kristen

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	11,900	$0.00	--
Grant/Award	Common Stock	10,400	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 11,900 shares (Direct); Common Stock — 37,639 shares (Direct)

Footnotes (1)

These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Form 4 Insider Transactions: What Each Field Means →

01/23/2026 - 06:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yen Kristen

(Last)

(First)

(Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/21/2026		A		10,400⁽¹⁾	A	$0	37,639⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee stock option (right to buy)	$43.65	01/21/2026		A		11,900		⁽³⁾	01/21/2036	Common Stock	11,900	$0	11,900	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

Remarks:

Officer title: SVP Global Clinical Operations and Patient Advocacy

	/s/ Anish Bhatnagar, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Soleno Therapeutics (SLNO) disclose for Kristen Yen?

The company disclosed that officer Kristen Yen received 10,400 restricted stock units of Common Stock and an employee stock option for 11,900 shares, both granted on January 21, 2026.

How many Soleno Therapeutics (SLNO) shares does Kristen Yen beneficially own after this Form 4?

Following the reported transactions, Kristen Yen beneficially owned 37,639 shares of Soleno Therapeutics Common Stock directly, in addition to 11,900 stock options.

What are the vesting terms of Kristen Yen’s RSUs at Soleno Therapeutics (SLNO)?

The 10,400 RSUs granted to Kristen Yen are scheduled to vest 100% on December 15, 2027, provided she continues as a service provider under the company’s 2014 Equity Incentive Plan through that date.

What are the key details of Kristen Yen’s stock option grant from Soleno Therapeutics (SLNO)?

The employee stock option covers 11,900 shares of Common Stock at an exercise price of $43.65 per share. Vesting begins on February 1, 2026, with 1/48th of the shares vesting each month, conditioned on continued service.

Is Kristen Yen a director or officer of Soleno Therapeutics (SLNO)?

According to the filing, Kristen Yen is an officer of Soleno Therapeutics, serving as SVP Global Clinical Operations and Patient Advocacy. She is not listed as a director or 10% owner.

Does the Soleno Therapeutics (SLNO) Form 4 involve any stock sales by Kristen Yen?

No stock sales are reported. The Form 4 reflects acquisitions of equity awards: 10,400 RSUs of Common Stock and an option for 11,900 shares, both granted for a price of $0 per unit.